The Inquisitor: New setbacks leave Elan even more vulnerable

The firm has been hit by the failure of its latest Alzheimer drug trials, and the imminent departure of Kelly Martin as chief executive, writes Richard Curran.

11th August, 2012
With the abandonment of Bapineuzumab intravenous, Elan may well become a takeover target.

Robert Ingram, the chairman of Elan, told shareholders last March that group chief executive Kelly Martin would be staying on until data from trials of its potential new Alzheimer's treatment Bapineuzumab were made available.

Ingram said the drug was potentially of "transformational significance" for the company. Last week's disappointing results, which saw it fail to get through clinical trials, may well end up being transformational for Elan, but not in the way Ingram had in...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago